Press ReleasesCeladon Pharmaceuticals Announces Home Office Approval Of Licence For...

Celadon Pharmaceuticals Announces Home Office Approval Of Licence For Commercial Sale Of GMP Cannabis



FURTHER to the announcement dated 16 January 2023, Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that its current Home Office licence has been successfully updated to allow the commercial sale of its high Δ9-tetrahydrocannabinol (“THC”) product, following the Company’s recent registration as a Good Manufacturing Practices (“GMP”) manufacturer by the UK Medicines and Healthcare products Regulatory Agency (“MHRA”).


  • Receipt of updated Home Office licence enables Celadon to commence the commercial supply of its GMP pharmaceutical cannabis product
  • GMP registration is understood to be the first such registration of a UK pharmaceutical facility for high THC cannabis active pharmaceutical ingredient (“API”) since the legalisation of medical cannabis in 2018
  • GMP registration and a Home Office licence are required in order to sell high-THC medicinal cannabis in the UK
  • Celadon becomes one of a small number of companies globally with the capability to produce an EU-GMP grade high-THC cannabinoid API

As set out in the 16 January 2023 announcement, Celadon notified the Home Office to request an update to its existing licence to reflect its GMP status. Celadon has today received confirmation from the Home Office that it has updated the Company’s current licence to reflect Celadon’s new GMP status. Celadon now holds a Home Office licence that enables it to commercially supply its GMP pharmaceutical cannabis product to third parties.

The Directors believe Celadon has now become one of a limited number of companies globally with the approvals in place to cultivate and manufacture EU-GMP grade high-THC medicinal cannabis and is understood to be the first for high-THC API in the UK since medicinal cannabis was legalised in 2018. Within the UK, patients prescribed medicinal cannabis are reliant on imported product, often facing lengthy delays and high costs, and by becoming a UK-based producer, Celadon is in a prime position to alleviate the issues currently faced by patients.

James Short, Chief Executive Officer of Celadon said:

Following our milestone GMP certification, our updated Home Office licence now gives Celadon the opportunity to pursue revenue through the sale of our medicines, and to becoming a partner of choice in the pharmaceutical cannabis sector.

It has been a great start to 2023 for Celadon and we continue to work hard to get our products to market and, most importantly, to the patients that need our medicines most.”

Latest news

European Cannabis Stocks Review: Celadon Shares Spike 150% On Licence Update, OCT Continues Recovery, & Creso Pharma Censured By ASX

Celadon Pharmaceuticals  Celadon Pharmaceuticals stock has skyrocketed by more than 150% this week following the announcement that its current Home...

Benefits of F1 Cannabis Hybrids from Royal Queen Seeds

F1 hybrids have revolutionised the way we grow and use plants. Now, F1 cannabis seeds are bringing growers, smokers,...

Proposed Changes To Germany’s Medical Cannabis Framework Would ‘Seriously Impact Both Patients And Industry’ If Brought In Tomorrow

TOMORROW, Germany’s Federal Joint Committee (G-BA) is expected to announce major changes to the country’s medical cannabis framework.  These could...

Will Twitter’s ‘Relaxation’ On Cannabis Advertising Help Break The Industry’s Social Media Ad Embargo?

TWITTER has become the first major social media platform to openly allow the advertisement of cannabis brands.  Since the new...

Kanabo Launches New Online Medical Cannabis Clinic ‘Treat It’, Offering Access To Doctors In ‘Less Than 24 Hours’

KANABO Group has today announced the launch of a new online medical cannabis clinic for pain management, Treat It.  The...

European Cannabis Stocks Review: Akanda Implement’s 1-10 Stock Consolidation, IMC Slashes 20% Of Staff, & More From DanCann Pharma

Akanda Akanda has become the latest NASDAQ-listed cannabis company to enact a stock consolidation in order to avoid delisting from...

Must read

You might also likeRELATED
Recommended to you